	US 12,426,579 B2
	Immunodeficient mouse
Takeshi Takahashi, Kanagawa (JP); and Ikumi Katano, Kanagawa (JP)
Assigned to Central Institute for Experimental Animals, Kanagawa (JP)
Appl. No. 17/251,272
Filed by Central Institute for Experimental Animals, Kanagawa (JP)
PCT Filed Sep. 25, 2019, PCT No. PCT/JP2019/037675 § 371(c)(1), (2) Date Dec. 11, 2020, PCT Pub. No. WO2020/067199, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 2018-181930 (JP), filed on Sep. 27, 2018; and application No. 2018-217229 (JP), filed on Nov. 20, 2018.
Prior Publication US 2021/0259221 A1, Aug. 26, 2021
Int. Cl. A01K 67/027 (2024.01); A01K 67/0276 (2024.01); A01K 67/0278 (2024.01)

CPC A01K 67/0278 (2013.01) [A01K 67/0276 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0387 (2013.01)]

18 Claims

1. A genetically modified immunodeficient mouse in which a mutation is introduced into the gene of the IL-2 receptor γ chain to disrupt the IL-2 receptor γ chain; which has a mutation of a gene involved in rearrangement of antigen receptor genes of T cells and B cells at both allelic loci; and in which Fcer1g gene and Fcgr2b gene are deficient.